Geneos Wealth Management’s NovoCure NVCR Stock Holding History

Geneos Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.23K	Hold	213	–	–	﹤0.01%	2264
2026 Q1	$2.32K	Hold	213	–	–	﹤0.01%	2288
2025 Q4	$2.75K	Hold	213	–	–	﹤0.01%	2271
2025 Q3	$2.75K	Hold	213	–	–	﹤0.01%	2265
2025 Q2	$3.79K	Hold	213	–	–	﹤0.01%	2649
2025 Q1	$3.8K	Buy	+213	New	+$4.84K	﹤0.01%	2599
2023 Q4	–	Sell	-40	Closed	-$646	–	2147
2023 Q3	$646	Hold	40	–	–	﹤0.01%	2075
2023 Q2	$1.66K	Buy	+40	New	+$2.48K	﹤0.01%	1956
2022 Q4	–	Sell	-90	Closed	-$6K	–	2071
2022 Q3	$6K	Sell	90 -45	-33%	-$3.51K	﹤0.01%	1654
2022 Q2	$9K	Hold	135	–	–	﹤0.01%	2001
2022 Q1	$11K	Sell	135 -10	-7%	-$737	﹤0.01%	2056
2021 Q4	$10K	Buy	+145	New	+$14.6K	﹤0.01%	2184
2019 Q1	–	Sell	-200	Closed	-$6K	–	2450
2018 Q4	$6K	Buy	+200	New	+$7.31K	﹤0.01%	1943
2016 Q2	–	Sell	-100	Closed	-$1K	–	1830
2016 Q1	$1K	Buy	+100	New	+$1.44K	﹤0.01%	1738

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Geneos Wealth Management's NVCR Position: Q2 2026 in Review

Geneos Wealth Management held its NovoCure (NVCR) position steady in Q2 2026 at 213 shares worth $3.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2264.

Geneos Wealth Management first reported a position in NVCR in Q1 2016 and has held it in 14 quarters since. The position peaked at $11K in Q1 2022. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Geneos Wealth Management held 213 shares of NovoCure worth $3.23K as of Q2 2026.
Geneos Wealth Management left its NovoCure share count unchanged in Q2 2026.
NovoCure made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #2264 holding.
Geneos Wealth Management first reported a position in NovoCure in Q1 2016 and has held it in 14 quarters since.
Geneos Wealth Management's NovoCure position peaked at $11K in Q1 2022.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.